You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Development of a novel highly effective influenza vaccine

    SBC: Flugen, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Nitric Oxide Microfluidic Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development of PAR Pepducins as a Novel Antithrombotic Treatment

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Coronary artery disease remains the leading cause of death in the United States Platelets play an important role in the pathogenesis of acute coronary syndrome ACS as platelet activation aggregation and secretion are key components of arterial thrombus formation Despite dual anti platelet therapy for ACS and percutaneous coronary interventions PCI many patients sustain a high incidence u ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Novel commensal polysaccharide treats multiple sclerosis through Treg modulation

    SBC: SYMBIOTIX BIOTHERAPIES, INC.            Topic: NIAID

    Abstract Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease that is the most common neurological disease of young adults, affecting over 350,000 patients in the US and over 2.5 million patients worldwide. MS is a disease of high unmetmedical need, currently treatable with one of several approved drugs, all of which result in either immune modulation or significant immunosuppre ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. HLS Cyclic CAR peptide a targeted therapy for pulmonary hypertension

    SBC: VASCULAR BIOSCIENCES, INC.            Topic: NHLBI

    PUBLIC ABSTRACT This project in response to announcement HLS describes a development program for CARSKNKDC CAR a synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapies for the treatment of pulmonary hypertension PH PH is a disorder of elevated pulmonary vascular resistance characterized by ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Development Characterization and Commercialization of a Viably Frozen Patient Inclusive Hepatocellular Carcinoma Tumor Bank

    SBC: Woodland Pharmaceuticals LLC            Topic: 103

    Abstract Hepatocellular carcinoma HCC is a disease of growing incidence globally including in the US by per year With the recent success of anti viral therapies the etiology of HCC in the American population is projected to shift from viral HBV HCV hepatitis to primarily fatty liver disease in the near future Currently only one effective systemic therapy has been developed for HCC ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. UV emitting nanoparticles as novel radiation sensitizers targeting hypoxic cells

    SBC: Radiation Monitoring Devices, Inc.            Topic: 102

    Project Summary Abstract Radiation therapy is one of the primary therapeutic techniques for treating cancer Nearly two thirds of all cancer patients will receive radiation therapy during their illness with an average of radiation treatment episodes Although largely effective radiation therapy like other forms of cancer treatment has difficulty killing hypoxic regions within solid tumors ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Developing Heparan Sulfate Glycan Array

    SBC: Glycan Therapeutics LLC            Topic: NIGMS

    Project titleDeveloping heparan sulfate glycan array This proposal is aimed at developing a high throughput method to study the interactions between heparan sulfateHSand proteinsHS is a highly sulfated polysaccharide displaying a wide range of biological functionsGlycan Therapeutics is a company specialized in HS related research productsIn this proposalan HS array technique will be constructed us ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government